

30th September 2016

National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

Ref. no.: NSE/CM/Surveillance/6477 dated 30th September 2016


Dear Sir,

This has reference to your captioned letter.

In this regard, we request you to refer to our letter of even date (copy attached).

Thank you,

Yours faithfully,
For Cipla Limited



Mital Sanghvi
Company Secretary

Encl: As above

30th September 2016

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ


(3) SOCIETE DE LA BOURSE DE
LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

This is to inform you that US FDA recently concluded audit of our 3 manufacturing facilities at Goa and has issued 4 observations across these 3 facilities. These observations were primarily procedural in nature and the Company has already responded to these observations. We continue to operate our facilities with a high level of compliance & control.

Thank you,

Yours faithfully,
For Cipla Limited



Mital Sanghvi
Company Secretary